How An Inversion Is Paying Off Twice In Mylan’s Fight Against Teva … – Forbes


Pittsburgh Post-Gazette
How An Inversion Is Paying Off Twice In Mylan’s Fight Against Teva
Forbes
First off, it bolstered the company’s presence in the global generics marketplace where manufacturers like Canada-based Valeant Pharmaceuticals Valeant Pharmaceuticals, Isreal’s Teva Pharmaceuticals, and India-based Ranbaxy Laboratories have picked …
Teva Pharmaceutical Industries Limited (NYSE:TEVA) says ‘fully committed’ to Stock Newscast
Big Shareholder Backs Drugmaker Mylan’s Growth StrategyNew York Times

all 65 news articles >>

Source: pharmaceutical – Google News

Sharing information is key – Pharmaceutical Business News UK. Social Commerce and Social Media Management playing a big part. Suaju Ltd